Doug Lockyer

When Doug took the position of joint CEO (Business) at this startup bioinformatics firm, the founding scientists had barely penetrated their market, yet were in possession of a core technology that added significant value to, and significantly reduced the time and costs of, the protein identification process which many of the World's leading Biotech firms were competitively engaged in and heavily funded for.

see bio.com's introduction to mass spectrometry

Doug's goal was to either raise sufficient equity funding for rapid growth, leading to an IPO, or to initiate and negotiate an acquisition by a leading Biotech firm, while increasing software sales.

see biospace press release